TRACKING / TRIAL TRACKER
Neoantigen vaccine clinical trials: live tracker
Find active and notable personalized-cancer-vaccine trials by phase, sponsor, indication, recruiting status, and ClinicalTrials.gov update date.
106trials tracked5in Phase 339recruiting9featured
Popular trial searches
Jump to named sponsors, assets, and trial classes already present in the live ClinicalTrials.gov tracker.
Status
Phase
| Program / Title | Sponsor | Phase | Status | Indication | Primary completion | Last update |
|---|---|---|---|---|---|---|
| ★ FeaturedA Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)NCT05933577Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath-001 adjuvant melanoma, Phase 3 | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 3 | Active Not Recruiting | Melanoma | 2029-10-26 (est.) | 24 Sept 2025 |
| ★ FeaturedA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath NSCLC, Phase 3 | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 2030-06-25 (est.) | 17 Jul 2026 |
| ★ FeaturedA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACNCT05968326Autogene cevumeran (BNT122 / RO7198457), BioNTech + Genentech/Roche — adjuvant program | Genentech, Inc.+ BioNTech SE | Phase 2 | Recruiting | Adenocarcinoma, Pancreatic Ductal | 2031-01-01 (est.) | 7 Jul 2026 |
| ★ FeaturedAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)NCT03897881Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — KEYNOTE-942 randomized Phase 2b, adjuvant melanoma | ModernaTX, Inc.+ Merck Sharp & Dohme LLC | Phase 2 | Active Not Recruiting | Melanoma | 2032-11-30 (est.) | 3 Dec 2025 |
| ★ FeaturedA Clinical Trial Evaluating TG4050 in Head and Neck CancerNCT04183166TG4050, Transgene + NEC — adjuvant head & neck cancer | Transgene | Phase 1/2 | Active Not Recruiting | Squamous Cell Carcinoma of Head and Neck | 2027-12-30 (est.) | 16 Jan 2026 |
| ★ FeaturedA Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic MelanomaNCT05309421EVX-01, Evaxion Biotech — with pembrolizumab in advanced melanoma, Phase 2 | Evaxion Biotech A/S+ Merck Sharp & Dohme LLC | Phase 2 | Active Not Recruiting | Melanoma Stage IV, Unresectable Melanoma | 2025-09-30 (est.) | 22 Sept 2025 |
| ★ FeaturedNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsNCT04041310NOUS-209, Nouscom — microsatellite-unstable solid tumors, Phase 1/2 | Nouscom SRL+ Merck Sharp & Dohme LLC | Phase 1/2 | Active Not Recruiting | Solid Tumor, Adult | 2026-10-30 (est.) | 13 Feb 2026 |
| ★ FeaturedPersonalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMNCT02287428NeoVax personalized neoantigen peptide vaccine, Dana-Farber — with radiotherapy + pembrolizumab in newly diagnosed glioblastoma, Phase 1 | Dana-Farber Cancer Institute+ 4 | Phase 1 | Active Not Recruiting | Glioblastoma | 2027-02 (est.) | 17 Apr 2026 |
| ★ FeaturedGNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCNCT04251117GNOS-PV02, Geneos Therapeutics — with INO-9012 + pembrolizumab in advanced HCC, Phase 1/2 | Geneos Therapeutics | Phase 1/2 | Active Not Recruiting | HCC | 2024-11-29 | 22 Apr 2026 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNCT06904066 | National Cancer Institute (NCI) | Phase 1 | Recruiting | Malignancy, Hematologic, Neoplasms, Hematologic | 2029-04-30 (est.) | 17 Jul 2026 |
| Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseNCT06529822 | Washington University School of Medicine+ Natera, Inc. | Phase 1 | Recruiting | Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma | 2030-01-31 (est.) | 17 Jul 2026 |
| EWSR1 Immunotherapy in Ewing Sarcoma and DSRCTNCT07695311 | Rabi Hanna+ The Little Warriors Foundation | Phase 1 | Not Yet Recruiting | Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | 2029-10 (est.) | 16 Jul 2026 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerNCT03606967 | National Cancer Institute (NCI) | Phase 2 | Recruiting | Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | 2026-12-30 (est.) | 13 Jul 2026 |
| Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell CarcinomaNCT07686744 | Jian Lin | Phase 1 | Not Yet Recruiting | Renal Cell Carcinoma, Advanced | 2029-01-01 (est.) | 7 Jul 2026 |
| Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLCNCT07683832 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School+ Suzhou Abogen Biosciences Co., Ltd. | Phase EARLY_PHASE1 | Not Yet Recruiting | Non-Small Cell Lung Cancer NSCLC | 2028-12-31 (est.) | 6 Jul 2026 |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 3 | Recruiting | Carcinoma, Non-Small-Cell Lung | 2033-05-16 (est.) | 6 Jul 2026 |
| Pathologic and Immunologic Response After Ablative Radiation in Lung CancerNCT03603002 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase NA | Completed | Non-small Cell Lung Cancer Stage I | 2021-09-01 | 2 Jul 2026 |
| An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid TumorsNCT07680582 | Ruijin Hospital+ Suzhou Abogen Biosciences Co., Ltd. | Phase EARLY_PHASE1 | Recruiting | Solid Tumor | 2026-06-30 (est.) | 2 Jul 2026 |
| Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive GlioblastomaNCT07678138 | Huanhu Hospital Affiliated to Tianjin Medical University | Phase NA | Not Yet Recruiting | Glioblastoma | 2027-11-30 (est.) | 1 Jul 2026 |
| A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After SurgeryNCT07676890 | West China Hospital | Phase 1 | Not Yet Recruiting | Ovarian Cancer, mRNA Vaccine | 2028-05-30 (est.) | 30 Jun 2026 |
| RGL-270 + ICI in Advanced NSCLCNCT07652125 | Guangdong Association of Clinical Trials+ Shanghai Regenelead Theraples,Co,Ltd. | Phase NA | Recruiting | NSCLC | 2027-12-31 (est.) | 30 Jun 2026 |
| Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerNCT05013216 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 2 | Phase 1 | Recruiting | High Risk Cancer, Pancreatic Cancer | 2027-10-01 (est.) | 30 Jun 2026 |
| Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas CancerNCT06205849 | University of California, San Diego+ 2 | Phase 1 | Recruiting | Pancreatic Cancer | 2028-08 (est.) | 25 Jun 2026 |
| Immune Modulatory DC Vaccine Against Brain TumorNCT03914768 | Shenzhen Geno-Immune Medical Institute | Phase 1 | Enrolling By Invitation | Diffuse Intrinsic Pontine Glioma or Glioblastoma | 2029-05-31 (est.) | 23 Jun 2026 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 | Mayo Clinic | Phase 1/2 | Recruiting | Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 2028-03-31 (est.) | 23 Jun 2026 |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerNCT02600949 | M.D. Anderson Cancer Center+ National Cancer Institute (NCI) | Phase 1 | Enrolling By Invitation | Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | 2027-05-31 (est.) | 17 Jun 2026 |
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer PatientsNCT07300475 | Washington University School of Medicine | Phase 1 | Not Yet Recruiting | Triple Negative Breast Cancer | 2030-05-31 (est.) | 15 Jun 2026 |
| Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced SarcomaNCT07648069 | Sun Yat-sen University | Phase 1 | Recruiting | Soft Tissue Sarcoma (STS), Osteosarcoma | 2026-12-31 (est.) | 15 Jun 2026 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid LeukemiaNCT04214249 | National Cancer Institute (NCI) | Phase 2 | Active Not Recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | 2024-11-27 | 12 Jun 2026 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesNCT04068194 | National Cancer Institute (NCI) | Phase 1/2 | Active Not Recruiting | Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | 2027-07-01 (est.) | 11 Jun 2026 |
| 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCCNCT05317000 | Barbara Burtness+ National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 | Recruiting | Squamous Cell Carcinoma of Head and Neck | 2028-06-30 (est.) | 10 Jun 2026 |
| Ex Vivo Expansion (ACT-X)NCT07137312 | Mayo Clinic | — | Recruiting | Solid Tumor, Healthy | 2028-10-31 (est.) | 9 Jun 2026 |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsNCT03289962 | Genentech, Inc.+ BioNTech SE | Phase 1 | Completed | Melanoma, Non-Small Cell Lung Cancer | 2025-07-01 | 8 Jun 2026 |
| Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant TherapyNCT07612930 | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | — | Available | Pancreatic Ductal Adenocarcinoma (PDAC) | — | 29 May 2026 |
| Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRASNCT07614048 | Providence Health & Services | — | Temporarily Not Available | PDAC - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | — | 29 May 2026 |
| Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerNCT02883062 | National Cancer Institute (NCI) | Phase 2 | Active Not Recruiting | Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7 | 2019-12-18 | 28 May 2026 |
| A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.NCT03219450 | Dana-Farber Cancer Institute+ 3 | Phase 1 | Recruiting | Lymphocytic Leukemia | 2027-07-31 (est.) | 28 May 2026 |
| Preventive Dendritic Cell Vaccination for Lynch Syndrome CarriersNCT07609901 | Radboud University Medical Center+ Dutch National Health Care Institute | Phase 3 | Not Yet Recruiting | Lynch Syndrome | 2032-10-01 (est.) | 27 May 2026 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast CancerNCT06631092 | NEC Bio B.V+ NEC Bio Therapeutics | Phase 1/2 | Recruiting | Triple Negative Breast Cancer | 2027-12-31 (est.) | 26 May 2026 |
| To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsNCT07594964 | Shenzhen Xinhe Biomedical | Phase 1 | Recruiting | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC) | 2029-10-30 (est.) | 19 May 2026 |
| A Study of DCTY1102 Injection in Participants With Advanced Solid TumorsNCT07014878 | Beijing DCTY Biotech Co.,Ltd. | Phase 1 | Not Yet Recruiting | Colorectal Cancer, Lung Cancer | 2028-08 (est.) | 18 May 2026 |
| Nivolumab in Biochemically Recurrent dMMR Prostate CancerNCT04019964 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ Bristol-Myers Squibb | Phase 2 | Completed | Prostate Cancer, Recurrent Prostate Cancer | 2025-04-23 | 15 May 2026 |
| Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic CancerNCT07587827 | Centre Georges Francois Leclerc | Phase 1 | Not Yet Recruiting | Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer | 2027-05-01 (est.) | 14 May 2026 |
| Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaNCT03604978 | National Cancer Institute (NCI) | Phase 1/2 | Active Not Recruiting | Grade 2 Meningioma, Grade 3 Meningioma | 2027-03-19 (est.) | 13 May 2026 |
| YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate CancerNCT07583160 | Changhai Hospital | Phase 1 | Enrolling By Invitation | Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC) | 2028-06-01 (est.) | 13 May 2026 |
| An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid TumorsNCT07583953 | Suzhou Abogen Biosciences Co., Ltd.+ The First Affiliated Hospital of Soochow University | Phase EARLY_PHASE1 | Not Yet Recruiting | Solid Tumors | 2029-01-31 (est.) | 13 May 2026 |
| Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid TumorsNCT07560943 | West China Hospital | Phase 1 | Recruiting | Cancer | 2027-04-28 (est.) | 11 May 2026 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMNCT07377435 | David Avigan+ The V Foundation | Phase 1 | Recruiting | Multiple Myeloma, Refractory Multiple Myeloma | 2028-03-01 (est.) | 8 May 2026 |
| A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)NCT06295809 | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 2/3 | Terminated | Carcinoma, Squamous Cell, Skin Neoplasms | 2026-03-05 | 8 May 2026 |
| Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated GlioblastomaNCT04015700 | Washington University School of Medicine+ 3 | Phase 1 | Active Not Recruiting | Glioblastoma | 2022-05-13 | 7 May 2026 |
| QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.NCT03552718 | NantBioScience, Inc. | Phase 1 | Completed | Colorectal Cancer, Breast Cancer | 2025-03-18 | 7 May 2026 |
| A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple MyelomaNCT06799026 | David Avigan+ Pfizer | Phase 1 | Recruiting | Multiple Myeloma, Relapse Multiple Myeloma | 2028-09-01 (est.) | 7 May 2026 |
| Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System TumorsNCT03988283 | Washington University School of Medicine+ Children's Discovery Institute | Phase 1 | Recruiting | Pediatric Recurrent Central Nervous System Tumors | 2029-03-31 (est.) | 7 May 2026 |
| Preventive Dendritic Cell Vaccination for Lynch SyndromeNCT07412197 | Radboud University Medical Center+ Dutch Cancer Society | Phase 1/2 | Not Yet Recruiting | Lynch Syndrome | 2029-12 (est.) | 6 May 2026 |
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)NCT07430202 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 3 | Phase 1 | Not Yet Recruiting | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | 2030-08 (est.) | 6 May 2026 |
| Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to SurgeryNCT05111353 | Washington University School of Medicine+ 4 | Phase 1 | Completed | Pancreas Cancer, Pancreatic Cancer | 2025-11-03 | 6 May 2026 |
| Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaNCT05743595 | Washington University School of Medicine+ 3 | Phase 1 | Active Not Recruiting | Unmethylated Glioblastoma | 2026-04-07 | 4 May 2026 |
| Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After SurgeryNCT04968366 | Beijing Tiantan Hospital+ ZhongSheng BioTech Inc. | Phase 1 | Completed | Glioblastoma Multiforme of Brain | 2024-04-30 | 4 May 2026 |
| Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance TherapyNCT07551037 | Fujian Medical University Union Hospital | Phase 1 | Recruiting | Acute Myeloid Leukemia, Personalized Active Immunotherapy | 2026-09-01 (est.) | 1 May 2026 |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabNCT04266730 | UNC Lineberger Comprehensive Cancer Center | Phase 1 | Suspended | Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | 2027-06-01 (est.) | 23 Apr 2026 |
| Personalized Neoantigen Cancer Vaccine for Patients With Solid TumorsNCT06614140 | Seqker Biosciences, Inc. | Phase 1/2 | Completed | Cancer, Solid Tumor, Adult | 2025-08-15 | 22 Apr 2026 |
| Resistance Exercise Training to Improve Bone and Articular Cartilage Health in WomenNCT05889598 | Loughborough University+ Versus Arthritis | Phase NA | Active Not Recruiting | Osteoporosis, Osteoarthritis | 2026-12-31 (est.) | 21 Apr 2026 |
| IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerNCT03655002 | City of Hope Medical Center+ National Cancer Institute (NCI) | Phase 1 | Active Not Recruiting | Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma | 2027-03-02 (est.) | 20 Apr 2026 |
| KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic CancerNCT07353645 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1/2 | Recruiting | Colorectal Cancer, Pancreatic Cancer | 2029-01-01 (est.) | 15 Apr 2026 |
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)NCT06141369 | Shanghai Jiao Tong University School of Medicine | Phase NA | Recruiting | Adrenal Cortical Carcinoma, Medullary Thyroid Cancer | 2026-12-30 (est.) | 9 Apr 2026 |
| A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid TumorNCT06682117 | Fudan University | Phase NA | Recruiting | Treatment, Neoantigen | 2026-12-30 (est.) | 2 Apr 2026 |
| Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant TherapyNCT06435351 | H. Lee Moffitt Cancer Center and Research Institute | Phase EARLY_PHASE1 | Recruiting | Breast Cancer, Triple Negative Breast Cancer | 2029-05 (est.) | 1 Apr 2026 |
| Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal CancerNCT07504523 | Ying Yuan, MD+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1 | Recruiting | Metastatic Colorectal Cancer (CRC) | 2027-12-31 (est.) | 1 Apr 2026 |
| Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung CancerNCT07504484 | Ying Yuan, MD+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1 | Completed | CRC (Colorectal Cancer), Non Small Lung Cancer | 2023-12-31 | 31 Mar 2026 |
| A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical ResectionNCT07495215 | Yinghua Xu | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC) | 2028-12-31 (est.) | 27 Mar 2026 |
| NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaNCT04930783 | Dana-Farber Cancer Institute+ Celldex Therapeutics | Phase 1 | Active Not Recruiting | Melanoma, Metastatic Melanoma | 2027-12-31 (est.) | 25 Mar 2026 |
| Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular LymphomaNCT03361852 | Dana-Farber Cancer Institute | Phase 1 | Active Not Recruiting | Follicular Lymphoma | 2026-12-31 (est.) | 25 Mar 2026 |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced CancersNCT03568058 | Aaron Miller | Phase 1 | Completed | Advanced Cancer | 2022-12-12 | 24 Mar 2026 |
| Low-Level Laser Therapy for Osgood-Schlatter or Sever Pain in Youth AthletesNCT07446517 | Medical University of Gdansk | Phase NA | Recruiting | Osgood-Schlatter Disease, Sever's Disease | 2027-02-01 (est.) | 17 Mar 2026 |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGNCT04943848 | Ann & Robert H Lurie Children's Hospital of Chicago+ 3 | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | 2026-09 (est.) | 17 Mar 2026 |
| A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian CancerNCT07455071 | Peking University Third Hospital | Phase NA | Not Yet Recruiting | HRD-negative Epithelial Ovarian Cancer | 2027-09-30 (est.) | 16 Mar 2026 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerNCT05098210 | Fred Hutchinson Cancer Center+ Amazon, Inc. | Phase 1 | Recruiting | Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | 2027-11-01 (est.) | 12 Mar 2026 |
| Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsNCT05078866 | National Cancer Institute (NCI) | Phase 1/2 | Active Not Recruiting | Colorectal Carcinoma, Lynch Syndrome | 2025-04-16 | 3 Mar 2026 |
| Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric CancerNCT07298200 | Jia Wei+ NeoCura | Phase 1 | Recruiting | Advanced Gastric Cancer | 2028-06 (est.) | 25 Feb 2026 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic EngineeringNCT04426669 | Intima Bioscience, Inc.+ Masonic Cancer Center, University of Minnesota | Phase 1/2 | Completed | Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | 2025-05-28 | 23 Feb 2026 |
| Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesNCT03929601 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)+ National Institutes of Health (NIH) | Phase 2 | Active Not Recruiting | Type 1 Diabetes Mellitus | 2027-03-31 (est.) | 19 Feb 2026 |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric GliomaNCT06342908 | Jonsson Comprehensive Cancer Center | Phase 1 | Active Not Recruiting | Diffuse Hemispheric Glioma, H3 G34-Mutant | 2027-03-08 (est.) | 17 Feb 2026 |
| XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic CancerNCT06353646 | Wu Wenming+ NeoCura | Phase NA | Recruiting | Pancreatic Cancer | 2026-06 (est.) | 13 Feb 2026 |
| Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal CancerNCT07329894 | Beijing GoBroad Hospital+ NeoCura | Phase 1 | Recruiting | Gastrointestinal Cancer | 2027-08 (est.) | 12 Feb 2026 |
| NeoVax Plus Ipilimumab in Renal Cell CarcinomaNCT02950766 | Patrick Ott, MD, PhD+ 2 | Phase 1 | Active Not Recruiting | Kidney Cancer | 2027-12-31 (est.) | 3 Feb 2026 |
| Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical ResectionNCT07368803 | Yifan Wang+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1/2 | Recruiting | Biliary Malignant Tumors | 2027-09-30 (est.) | 3 Feb 2026 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaNCT03082534 | University of California, San Diego+ Merck Sharp & Dohme LLC | Phase 2 | Completed | HNSCC, Lip SCC | 2025-07-21 | 28 Jan 2026 |
| Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed GlioblastomaNCT07365280 | ZSky Biotech Inc | Phase 2 | Not Yet Recruiting | Glioblastoma | 2028-12-24 (est.) | 26 Jan 2026 |
| Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid TumorsNCT06963697 | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | — | Available | Cancer | — | 15 Jan 2026 |
| A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid TumorsNCT05741242 | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Phase 1/2 | Enrolling By Invitation | Cancer, Solid Tumor | 2027-01 (est.) | 15 Jan 2026 |
| Clinical Study of XP-006 mRNA Vaccine for R/R B-NHLNCT07334574 | Ruijin Hospital+ Shanghai Xinpu BioTechnology Company Limited | Phase 1 | Not Yet Recruiting | B-cell Non-Hodgkin's Lymphoma (B-NHL) | 2028-01-01 (est.) | 13 Jan 2026 |
| COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal CancerNCT07328087 | Biogenea Pharmaceuticals Ltd.+ Interbalkan Medical Center, Thessaloniki, Greece | Phase EARLY_PHASE1 | Recruiting | Colorectal Cancer Metastatic, Colorectal Cancer Stage III | 2030-12-02 (est.) | 9 Jan 2026 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid TumorsNCT06631079 | NEC Bio B.V+ NEC Bio Therapeutics | Phase 1/2 | Active Not Recruiting | Solid Tumor | 2026-07-31 (est.) | 8 Jan 2026 |
| GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial CancerNCT07316361 | Biogenea Pharmaceuticals Ltd. | Phase EARLY_PHASE1 | Enrolling By Invitation | Endometrial Carcinoma, Endometrial Carcinoma Stage III | 2029-12-02 (est.) | 7 Jan 2026 |
| Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical StudyNCT07324473 | First Affiliated Hospital of Chongqing Medical University | Phase 2 | Not Yet Recruiting | Hepatocellular Carcinomas, Resistance to Immunotherapy | 2028-01-01 (est.) | 7 Jan 2026 |
| Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryNCT04161755 | Memorial Sloan Kettering Cancer Center+ 2 | Phase 1 | Active Not Recruiting | Pancreatic Cancer | 2026-11-11 (est.) | 7 Jan 2026 |
| Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaNCT03929029 | Dana-Farber Cancer Institute+ National Cancer Institute (NCI) | Phase 1 | Active Not Recruiting | Cutaneous Melanoma | 2022-12-27 | 5 Jan 2026 |
| A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaNCT01970358 | Patrick Ott, MD, PhD | Phase 1 | Completed | Melanoma | 2015-09 | 29 Dec 2025 |
| Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The KneeNCT06263270 | Cytonics Corporation | Phase 1 | Completed | Osteoarthritis, Knee, Osteoarthritis | 2025-03-15 | 26 Dec 2025 |
| Personalized Vaccine in Treating Patients With Smoldering Multiple MyelomaNCT03631043 | M.D. Anderson Cancer Center | Phase EARLY_PHASE1 | Completed | Smoldering Plasma Cell Myeloma | 2025-12-10 | 19 Dec 2025 |
| Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung CancerNCT07285434 | Biogenea Pharmaceuticals Ltd.+ https://interonco.gr/en/ | Phase EARLY_PHASE1 | Enrolling By Invitation | NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification | 2028-02-02 (est.) | 16 Dec 2025 |
| Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.NCT07077616 | Biogenea Pharmaceuticals Ltd.+ Naval Hospital, Athens | Phase EARLY_PHASE1 | Recruiting | Glioma | 2027-12-01 (est.) | 8 Dec 2025 |
| LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung CancerNCT05886439 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1/2 | Recruiting | Lung Cancer | 2027-05-30 (est.) | 8 Dec 2025 |
| DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaNCT04248569 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ Fibrolamellar Cancer Foundation | Phase 1 | Recruiting | Fibrolamellar Hepatocellular Carcinoma (FLC) | 2029-03-01 (est.) | 3 Dec 2025 |
| Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerNCT04117087 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 3 | Phase 1 | Active Not Recruiting | Colorectal Cancer, Pancreatic Cancer | 2027-06-01 (est.) | 3 Dec 2025 |
| Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical ResectionNCT05307835 | Second Affiliated Hospital, School of Medicine, Zhejiang University+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1 | Active Not Recruiting | Resectable Esophageal Cancer | 2026-06-30 (est.) | 2 Dec 2025 |
Named trial entries
mRNA-4157 / V940
Moderna/Merck intismeran autogene
Personalized mRNA vaccine studies with pembrolizumab, including Phase 3 melanoma and NSCLC programs.
- Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath-001 adjuvant melanoma, Phase 3NCT05933577 · Merck Sharp & Dohme LLC · Phase 3 · Active Not RecruitingClinicalTrials.gov
- Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath NSCLC, Phase 3NCT06077760 · Merck Sharp & Dohme LLC · Phase 3 · RecruitingClinicalTrials.gov
- Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — KEYNOTE-942 randomized Phase 2b, adjuvant melanomaNCT03897881 · ModernaTX, Inc. · Phase 2 · Active Not RecruitingClinicalTrials.gov
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · Merck Sharp & Dohme LLC · Phase 3 · RecruitingClinicalTrials.gov
+1 more matching trial in the table.
BNT122 / RO7198457
BioNTech/Genentech autogene cevumeran
Personalized mRNA vaccine program in adjuvant pancreatic cancer and related settings.
- Autogene cevumeran (BNT122 / RO7198457), BioNTech + Genentech/Roche — adjuvant programNCT05968326 · Genentech, Inc. · Phase 2 · RecruitingClinicalTrials.gov
- A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsNCT03289962 · Genentech, Inc. · Phase 1 · CompletedClinicalTrials.gov
Transgene + NEC
Transgene TG4050
Personalized viral-vector vaccine trial in adjuvant head-and-neck cancer.
- TG4050, Transgene + NEC — adjuvant head & neck cancerNCT04183166 · Transgene · Phase 1/2 · Active Not RecruitingClinicalTrials.gov
Evaxion Biotech
Evaxion EVX-01
Personalized peptide vaccine trial with pembrolizumab in advanced melanoma.
- EVX-01, Evaxion Biotech — with pembrolizumab in advanced melanoma, Phase 2NCT05309421 · Evaxion Biotech A/S · Phase 2 · Active Not RecruitingClinicalTrials.gov
Geneos Therapeutics
Geneos GNOS-PV02
Personalized DNA vaccine trial with INO-9012 and pembrolizumab in advanced HCC.
- GNOS-PV02, Geneos Therapeutics — with INO-9012 + pembrolizumab in advanced HCC, Phase 1/2NCT04251117 · Geneos Therapeutics · Phase 1/2 · Active Not RecruitingClinicalTrials.gov
Autologous DC
Dendritic-cell vaccine trials
Neoantigen-pulsed or preventive dendritic-cell vaccine studies currently present in the tracker.
- Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive GlioblastomaNCT07678138 · Huanhu Hospital Affiliated to Tianjin Medical University · Phase NA · Not Yet RecruitingClinicalTrials.gov
- Immune Modulatory DC Vaccine Against Brain TumorNCT03914768 · Shenzhen Geno-Immune Medical Institute · Phase 1 · Enrolling By InvitationClinicalTrials.gov
- Preventive Dendritic Cell Vaccination for Lynch Syndrome CarriersNCT07609901 · Radboud University Medical Center · Phase 3 · Not Yet RecruitingClinicalTrials.gov
- YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate CancerNCT07583160 · Changhai Hospital · Phase 1 · Enrolling By InvitationClinicalTrials.gov
+7 more matching trials in the table.
A live, registry-backed view of neoantigen and personalized-cancer-vaccine programs — personalized mRNA, peptide, viral-vector, and shared-antigen — organized by sponsor, phase, recruiting status, indication, and latest registry update.
No neoantigen vaccine is approved anywhere yet — every program is investigational, and inclusion here is not an endorsement. Background: Primer, companies landscape, FDA guide.
How to read this tracker
★ featured / landmark trial Recruiting Active / enrolling Not yet recruiting Completed Other(est.) estimated primary-completion dateSource: ClinicalTrials.gov, refreshed daily
FAQ
Is there an approved neoantigen vaccine?
No. As of today every neoantigen and personalized-cancer-vaccine program is investigational — none is approved by the FDA, EMA, or any major regulator. The furthest-advanced candidates are in Phase 3.
What phase is mRNA-4157 / intismeran autogene in?
Phase 3. The Moderna–Merck personalized neoantigen mRNA vaccine (mRNA-4157, intismeran autogene) is being tested with pembrolizumab in the INTerpath-001 trial as adjuvant therapy for resected high-risk melanoma, with additional Phase 3 indications underway.
How do I find active neoantigen vaccine clinical trials?
Use the tracker table to filter for recruiting studies, sponsor, phase, or indication. Each row links directly to its ClinicalTrials.gov record, where eligibility criteria, sites, contacts, and protocol details are maintained by the study sponsor or registry.
Which neoantigen vaccine trials are closest to approval?
The closest programs are the Phase 3 personalized mRNA vaccine trials, especially Moderna and Merck's intismeran autogene program in melanoma and lung-cancer settings. Phase alone is not proof of approval likelihood; pivotal endpoints, safety, manufacturing reliability, and regulator review still decide the outcome.
How current is this tracker?
It is auto-refreshed daily from the ClinicalTrials.gov v2 API. The exact build time is shown as the last-updated date at the top of this page; each refresh re-pulls sponsor, phase, status, and last-update fields directly from the registry.
Where does this data come from?
ClinicalTrials.gov — the U.S. National Library of Medicine's public registry of clinical studies. Every row links to its source study record so you can verify the details and read the full protocol summary.